Fig. 2. Other approaches to target NPM1-mutated AML.

NPM1-mutated AML can be targeted with selective inhibitors of menin to downregulate HOX/MEIS, with BCL-2 (venetoclax) to induce apoptosis and with inhibitors of the SYK pathway (entospletinib).